Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 13 May 2019 |
| ORION CORPORATION: ACQUISITION OF OWN SHARES 10.05.2019 | 10 May 2019 |
| ORION CORPORATION: ACQUISITION OF OWN SHARES 09.05.2019 | 9 May 2019 |
| ORION CORPORATION: ACQUISITION OF OWN SHARES 08.05.2019 | 8 May 2019 |
| ORION CORPORATION: ACQUISITION OF OWN SHARES 07.05.2019 | 7 May 2019 |